Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
27 Apr 2020
Long-term use of brivaracetam as an adjunctive treatment is well tolerated and effective in patients with focal seizures or primary generalized seizures, as shown in a study.
01 Apr 2019
Perampanel is safe and effective for treating refractory focal seizures in both Asian and non‐Asian populations, a study has found.
Elvira Manzano, 20 Jun 2018
A higher proportion of patients with systemic lupus erythematosus (SLE) experienced improvements in joint and skin symptoms with baricitinib 4 mg once daily vs placebo in a phase II randomized, double-blind, global study.

Novel chimeric monoclonal antibody offers hope in refractory colorectal cancer

01 Aug 2020

Ensituximab, a chimeric monoclonal antibody targeting a variant of MUC5AC, shows modest clinical activity with good safety profile in patients with refractory colorectal cancer, according to data from a phase II study.

The study included 63 patients with advanced, refractory cancer who expressed MUC5AC antigen in tumour tissue (median age, 58 years; 54 percent male). The mean time from initial diagnosis to study entry was 3.79 years, and all patients had undergone a median of three prior cancer-directed therapies.

All patients received infusions of ensituximab at 3 mg/kg every 2 weeks. Among 57 patients (90 percent) who were evaluable, the median overall survival (OS) was 6.8 months and longer than the 5.0 months observed in the historical control (p=0.007). Twelve patients (21 percent) achieved stable disease (SD) at the end of the first treatment course. Forty-nine patients were evaluable for progression-free survival, which had a mean duration of 70.4 days.

The study drug was well tolerated. Commonly reported treatment-related adverse events (AEs) were fatigue (38 percent), anaemia (30 percent), nausea (15 percent), vomiting (11 percent), increased bilirubin (9 percent), constipation (8 percent), decreased appetite (6 percent), and diarrhoea (6 percent).

Serious AEs potentially related to ensituximab occurred in four patients and included anaemia, nausea, increased bilirubin, and hypoxia. None of the patients discontinued treatment due to drug-related AEs.

The present data provide supporting rationale for investigating combination therapies containing ensituximab plus interleukin-15 or other agents, such as chemotherapy, to boost efficacy in the patient population, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
27 Apr 2020
Long-term use of brivaracetam as an adjunctive treatment is well tolerated and effective in patients with focal seizures or primary generalized seizures, as shown in a study.
01 Apr 2019
Perampanel is safe and effective for treating refractory focal seizures in both Asian and non‐Asian populations, a study has found.
Elvira Manzano, 20 Jun 2018
A higher proportion of patients with systemic lupus erythematosus (SLE) experienced improvements in joint and skin symptoms with baricitinib 4 mg once daily vs placebo in a phase II randomized, double-blind, global study.